Malignant bowel obstruction in advanced ovarian cancer

Future Oncol. 2017 Mar;13(6):513-521. doi: 10.2217/fon-2016-0431. Epub 2017 Jan 18.

Abstract

Aim: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood.

Methods: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO.

Results: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01).

Conclusion: The Manchester Bowel Obstruction Score may aide treatment stratification.

Keywords: Manchester Bowel Obstruction Score; bowel obstruction; ovarian cancer; prognostic score.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Disease Management
  • Female
  • Humans
  • Intestinal Obstruction / diagnosis*
  • Intestinal Obstruction / etiology*
  • Intestinal Obstruction / surgery
  • Intestinal Obstruction / therapy
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Staging
  • Ovarian Neoplasms / complications*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / pathology*
  • Proportional Hazards Models
  • Retrospective Studies
  • Treatment Outcome